Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer

John Sarantopoulos, Monica M. Mita, Michael J. Birrer, Lee D. Cranmer, Luis T. Campos, Xiaoping Zhang, Penelope Bristow, Hidekuni Kaito, Vincent Strout, Luis H. Camacho

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Background: KHK2866 is a recombinant, humanized, non-fucosylated, monoclonal antibody directed at heparin-binding epidermal growth factor-like growth factor (HB-EGF). Objective: To determine the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, potential immunogenicity, and preliminary clinical efficacy of KHK2866 monotherapy in patients with advanced and refractory cancer in a first-in-human, phase 1 study. Materials and Methods: Using a standard 3 + 3 dose-escalation design, 20 patients received KHK2866 (0.3, 1, and 3 mg/kg) intravenously once weekly. Two additional patients received 0.1 mg/kg in a cohort which was subsequently added following protocol amendment. Results: The first three patients enrolled experienced grade 2 hypersensitivity (acute infusion reactions) after the first dose of KHK2866. After prophylactic treatment with an H1-blocker and corticosteroids in subsequently recruited patients, two grade 2 hypersensitivity reactions were observed in the remaining 19 patients. Grade 2/3 neurotoxicity appeared to be dose-limiting at 3 mg/kg in the original dose-escalation cohorts (n = 2), at 1 mg/kg in the MTD dose expansion cohort (n = 1), and at 0.1 mg/kg (n = 1). Neurotoxicity was manifested as complex partial seizure activity, aphasia, and confusion after first-dose administration. Pharmacokinetic exposure to KHK2866 increased proportionally to dose. Mean elimination half-life was 71.9–118 h over the dose range from 0.3 to 3 mg/kg. All KHK2866 doses decreased serum free HB-EGF levels, generally below the lower limit of quantification. Conclusions: The study was terminated because of neuropsychiatric toxicity. The only predictive factor for neuropsychiatric toxicity was administration of KHK2866. These effects were reversible, but were not predictable. Their etiology is not presently understood. [Study registered at ClinicalTrials.gov #NCT0179291] [MediaObject not available: see fulltext.]

Original languageEnglish (US)
Pages (from-to)317-327
Number of pages11
JournalTargeted Oncology
Volume11
Issue number3
DOIs
StatePublished - Jun 1 2016

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer'. Together they form a unique fingerprint.

  • Cite this

    Sarantopoulos, J., Mita, M. M., Birrer, M. J., Cranmer, L. D., Campos, L. T., Zhang, X., Bristow, P., Kaito, H., Strout, V., & Camacho, L. H. (2016). Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer. Targeted Oncology, 11(3), 317-327. https://doi.org/10.1007/s11523-015-0394-5